TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8772604
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin (200 IU daily for 5 days/week) plus 1000 mg calcium daily
Study: 26119844
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (1000 mg daily)
Study: 1630044
Drug: Regular beta-agonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular beta-agonist inhalation
Study: 1630044
Drug: As required
Normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: As required beta-agonist inhalation
Study: 31592623
Drug: 3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/kg of CHO beverage
Study: 16766544
Drug: Isoflavone-containing soy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-containing soy-based nutritional supplements for 8 weeks
Study: 11422000
Drug: Anastrozole (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (7 mg loading dose on day 1, followed by 1 mg daily on days 2-11)
Study: 3573541
Drug: L-triiodothyronine (T3)
Normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-triiodothyronine (T3) treatment
Study: 3573541
Drug: Sodium ipodate
Normalized name: ipodate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ipodate treatment
Study: 28724041
Drug: Rhubarb (30.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb (30.0 g/d) for 7 days
Study: 28724041
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for 7 days
Study: 25542311
Drug: ABVE‐PC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE‐PC + 21 Gy involved field radiation therapy (IFRT)
Study: 23680435
Drug: Escitalopram (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (dose range around 10-15 mg/d)
Study: 15080852
Drug: Patient-controlled on-demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled on-demand treatment with esomeprazole, 20 mg daily
Study: 15080852
Drug: General practitioner-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 2 weeks
Study: 15080852
Drug: General practitioner-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner-controlled intermittent treatment with esomeprazole, 40 mg daily for 4 weeks
Study: 2475323
Drug: Opioid meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid meperidine (150 mg, p.o.)
Study: 2475323
Drug: Antidepressant imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant imipramine (100 mg, p.o.)
Study: 780063
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oxprenolol daily
Study: 780063
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg diazepam daily
Study: 27161285
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing Cichorium intybus root extract with UV filters
Study: 27161285
Drug: Formulations containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations containing Cichorium intybus root extract without UV filters
Study: 27161285
Drug: Vehicle formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle formulations containing UV filters
Study: 27161285
Drug: Vehicle formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle formulations without UV filters
Study: 25626920
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin (1 mg/mL) for three consecutive months
Study: 25626920
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (10 mg/mL) for three consecutive months
Study: 25626920
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin (1 mg/mL)
Study: 25626920
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (10 mg/mL)
Study: 21546927
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein breakfast (NP; 18 ± 1 g protein)
Study: 21546927
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein breakfast (HP; 50 ± 1 g protein)
Study: 20396724
Drug: Poetam and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poetam and anaferon (pediatric formulation) administered in combination with iron preparation
Study: 11451697
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg orally once daily
Study: 11451697
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg orally once daily
Study: 10052247
Drug: Etoposide 80
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 80 mg/m2 day 1-3, folinic acid 100 mg/m2 day 1-3, 5-fluorouracil 340 mg/m2 day 1-3, and epirubicin 60 mg/m2 day 1, repeated every three weeks
Study: 24444280
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus desmopressin (0.3 μg/kg)
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment at 2.2 bar
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment at 2.5 bar
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment (both protocols)
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment with positive expectation
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment with indifferent expectation
Study: 17274312
Drug: HBO2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HBO2 treatment with negative expectation
Study: 12599053
Drug: Rhesus monkey
Normalized name: rabies vaccine,adsorbed,rhesus monkey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus monkey rotavirus-based quadrivalent vaccine (4 x 10^5 plaque-forming units/dose)
Study: 12599053
Drug: Rhesus monkey
Normalized name: rabies vaccine,adsorbed,rhesus monkey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus monkey rotavirus-based quadrivalent vaccine
Study: 8841152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan 1 hour before 50 mg quinidine
Study: 8841152
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg quinidine
Study: 8841152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan (poor metabolizers)
Study: 8841152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan (extensive metabolizers with quinidine)
Study: 8841152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dextromethorphan (extensive metabolizers)
Study: 1738578
Drug: Vibratory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibratory stimulation with naloxone (0.4 mg)
Study: 27655761
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (HFM) - 250 mL (520 kcal) consisting of rapeseed oil (440 kcal), emulsifier, sucrose, flavor cocktail
Study: 11783207
Drug: CHM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHM plus chemotherapy
Study: 11783207
Drug: Single chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single chemotherapy
Study: 1768539
Drug: Low-dose adrenaline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenaline infusions
Study: 1768539
Drug: Phenylephrine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusions
Study: 29858149
Drug: Moxidectin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (8 mg) plus Albendazole (400 mg)
Study: 29858149
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) plus Oxantel Pamoate (25 mg/kg)
Study: 29858149
Drug: Moxidectin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (8 mg) plus Tribendimidine (200 mg or 400 mg)
Study: 29858149
Drug: Moxidectin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (8 mg) alone
Study: 10873672
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (400 mg/day for 5 weeks)
Study: 7680374
Drug: Pamidronate (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (high dose 600 mg/d and low dose 300 mg/d)
Study: 7680374
Drug: Pamidronate (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (low dose 300 mg/d)
Study: 27318866
Drug: Dual low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual low-density lipoprotein cholesterol-lowering therapy (DLLT) with statin-ezetimibe combination
Study: 22181006
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.05 μg/kg/min
Study: 22181006
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.08 μg/kg/min
Study: 22181006
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at 0.10 μg/kg/min
Study: 20105045
Drug: Bolus administered
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administered 15 min before meal
Study: 20105045
Drug: Bolus administered
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administered just before meal
Study: 20105045
Drug: Bolus administered
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administered just after meal
Study: 10073326
Drug: Trimetrexate, leucovorin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetrexate, leucovorin, and dapsone administered for 21 +/- 3 days; trimetrexate glucuronate, 45 mg/m2; leucovorin, 20 mg/m2; dapsone, 100 mg daily
Study: 2291659
Drug: Cefmetazole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole 0.5 g
Study: 2291659
Drug: Cefmetazole 1
Normalized name: cefmetazole 1 g/50 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole 1 g
Study: 2291659
Drug: Cefmetazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (all doses)
Study: 31704504
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) + full-mouth ultrasonic scaling (FMUS)
Study: 25872653
Drug: Trauma-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused cognitive behaviour therapy (TF-CBT)
Study: 24672232
Drug: C. domestica
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. domestica extracts 1,500 mg/day for 4 weeks
Study: 24672232
Drug: Ibuprofen 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1,200 mg/day for 4 weeks
Study: 20683042
Drug: Clonazepam (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion)
Study: 17055120
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (7.2 g/day, providing 1.1 g/day of 20:5 (n‐3) and 0.7 g/day of 22:6 (n‐3) fatty acids)
Study: 10465179
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg/day) for 6 weeks
Study: 7611726
Drug: Transfemoral, venous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfemoral, venous intradural infusions of urokinase
Study: 2171332
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (Premarin) 50 mg daily
Study: 6123336
Drug: Fentanyl 0.0066
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.0066 mg kg‐1 i.v. (group A)
Study: 6123336
Drug: Fentanyl 0.0066
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.0066 mg kg‐1 i.v. followed by almitrine 0.5 mg kg‐1 i.v. (group B)
Study: 6123336
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of almitrine 0.5 mg kg‐1 and fentanyl 0.0066 mg kg‐1 (group C)
Study: 22134132
Drug: Solanezumab (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (0.5, 1.5, 4.0, and 10.0 mg/kg)
Study: 19864308
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion maintained at a target organ concentration of 1.5 ng ml‐1 until extubation
Study: 19864308
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (remifentanil infusion stopped at the end of surgery)
Study: 16319704
Drug: Treatment provided
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment provided to high-stress group
Study: 16319704
Drug: Treatment provided
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment provided to low-stress group
Study: 16319704
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment satisfaction for all patients
Study: 7659811
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 mcg vaginal tablet)
Study: 2444306
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg bd)
Study: 12473698
Drug: 1.50 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.50 mg/mL rhBMP-2
Study: 24357574
Drug: 1-day cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day cognitive-behavioural therapy (CBT) self-confidence workshops
Study: 20597564
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight
Study: 20597564
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily
Study: 18414360
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg/kg)
Study: 27350144
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection
Study: 10325515
Drug: Combined endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endocrine therapy for 3 or 6 months
Study: 2015969
Drug: recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant DNA hGH (rhGH; 0.1 mg.kg‐1.day‐1)
Study: 2015969
Drug: prednisone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone (0.8 mg.kg‐1.day‐1)
Study: 2015969
Drug: rhGH and
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH and prednisone (combined treatment)
Study: 26854877
Drug: Removable partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable partial dentures (n = 53) or implant‐supported fixed partial dentures (n = 19)
Study: 26854877
Drug: Removable partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable partial dentures or implant‐supported fixed partial dentures (treatment group)
Study: 19641050
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload (500 mL of hydroxyethyl starch over 15-20 min before spinal anesthesia)
Study: 12197862
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy (coping skills training and cognitive therapy)
Study: 12197862
Drug: Non-specific supportive
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific supportive therapy
Study: 7846192
Drug: Oxazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (20 and 40 mg)
Study: 2903659
Drug: Esmolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (n = 12), continuous intravenous infusion, titrated from 2 to 24 mg/min
Study: 2903659
Drug: Propranolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (n = 11), oral, dose increased every 6 hours by 50 to 100%
Study: 30982351
Drug: Wheat samples
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat samples (17 different samples, 670 g/kg of each wheat sample in diet)
Study: 27547871
Drug: No steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroids after intraoperative bolus
Study: 21767283
Drug: Amitriptyline (12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (12.5-50 mg)
Study: 1383618
Drug: Pinacidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinacidil (25 mg up to 100 mg daily)
Study: 1383618
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg up to 80 mg daily)
Study: 3905561
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg D-penicillamine daily
Study: 3905561
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg D-penicillamine daily
Study: 3905561
Drug: D-penicillamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (both doses)
Study: 26073333
Drug: Drospirenone-only pill
Normalized name: drospirenone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-only pill
Study: 26073333
Drug: Desogestrel-only pill
Normalized name: desogestrel Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-only pill
Study: 24360131
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants
Study: 15334389
Drug: Pramlintide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (60 microg subcutaneous premeal injections 3 times daily for 5 days, IV infusion of 16 microg/h)
Study: 15334389
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous premeal injections 3 times daily for 5 days, IV infusion of placebo)
Study: 12845247
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (22 g for 48 hours)
Study: 11829830
Drug: Rhodiola compound
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola compound (RCO) 4 grams daily for 3-15 days after admission and 5-7 days post-operation
Study: 1925418
Drug: S-adenosylmethionine 800
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine 800 mg orally daily for six weeks
Study: 3925464
Drug: l-histidine 3g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-histidine 3g/day for 7 days
Study: 25147574
Drug: Real auricular
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real auricular point acupressure (APA) treatment
Study: 18485150
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent therapy
Study: 16305291
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg twice/day for 14 days
Study: 8873108
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (0.429 mg/kg)
Study: 8873108
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (0.214, 0.286, 0.357, and 0.429 mg/kg)
Study: 6506360
Drug: Short-term catheter
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term catheter treatment (1 day)
Study: 6506360
Drug: Long-term catheter
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term catheter treatment (14 days)
Study: 29393194
Drug: Vonoprazan-based triple
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan-based triple therapy
Study: 26946726
Drug: Pidotimod 10
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod 10 mL orally once a day for 90 days
Study: 25253679
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to attend a workshop on medication regimen adjustment during Ramadan
Study: 9579498
Drug: Morphine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (bolus dose of 100 microg/kg, followed by continuous infusion of 30 microg x kg(‐1) x h(‐1))
Study: 8624293
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X (COPP + ABVD) chemotherapy (CT-arm)
Study: 8624293
Drug: No consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No consolidation therapy
Study: 799995
Drug: halcinonide-neomycin-amphotericin cream
Normalized name: halcinonide / neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: halcinonide-neomycin-amphotericin cream
Study: 799995
Drug: hydrocortisone-iodochlorhydroxyquin cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone-iodochlorhydroxyquin cream
Study: 31102257
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg q4w
Study: 31102257
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg q6w